NovoCure (NVCR) Non Operating Income (2021 - 2026)

NovoCure (NVCR) has reported Non Operating Income for 6 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.

• Quarterly Non Operating Income fell 141.61% year-over-year to -$1.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 million (down 94.43% YoY) and the FY2025 annual result came in at $17.6 million, down 55.38% from the prior year.
• Non Operating Income declined to -$1.9 million in Q2 2026 per NVCR's latest filing, from -$1.8 million in the prior quarter.
• Over the last five years, Non Operating Income for NVCR reached as high as $13.2 million in Q4 2023 and fell as low as -$1.9 million in Q2 2026.
• A 5-year average of $6.6 million and a median of $8.4 million in 2023 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income surged 739.45% — and 2026, when it slumped 141.61%.
• Year by year, Non Operating Income stood at $10.4 million in 2022, then grew by 26.51% to $13.2 million in 2023, then plunged by 38.57% to $8.1 million in 2024, then plunged by 106.93% to -$561000.0 in 2025, then sank by 236.9% to -$1.9 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$1.9 million, -$1.8 million, and -$561000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.